 |
|
Chloroquine RetinopathyA Report of Eight Cases with ERG and Dark-Adaptation Findings
EDWARD OKUN, M.D.;
PETER GOURAS, M.D.;
HOWARD BERNSTEIN, M.D.;
LUDWIG VON SALLMANN, M.D.
Arch Ophthalmol. 1963;69(1):59-71.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Introduction
Chloroquine and its derivatives are being widely used today for the treatment of such diseases as disseminated lupus erythematosus, discoid lupus, light sensitivity eruptions, sarcoid, asthma, skin tumors, rheumatoid arthritis, and other collagen diseases. Corneal changes were noted soon after the introduction of these drugs, and have been well documented in the literature.1-14 According to Hobbs, Eadie, and Somerville,20 corneal changes occur in approximately one-third of patients on prolonged chloroquine therapy. Since these changes disappear after cessation of therapy, they are of relatively little clinical significance. However, the irreversible retinal changes recently observed by Hobbs, et al.18,20 represent a grave complication of chloroquine therapy. These findings consist of impaired central vision, peripheral constriction of the visual fields, marked attenuation of the retinal vasculature, pigmentary changes of the macula, and in some cases, peripheral pigmentary changes. Hobbs, et al. have now reported 4 cases of such changes,
. . . [Full Text PDF of this Article]
Author Affiliations
Bethesda, Md.
From the Ophthalmology Branch, National Institute of Neurological Diseases and Blindness, National Institutes of Health, Public Health Service, U.S. Department of Health, Education and Welfare.
Footnotes
Submitted for publication June 18, 1962.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
